Physician profile
Deepu Daniel
NPI 1447679808
$3,554.27
in general payments reported to CMS, 2019-2025
30 companies · $910 in 2025
The $910 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $218 · 2021: $510 · 2022: $473 · 2023: $464 · 2024: $580 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.04 |
| Education | $149.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $506.98 | 2019-2024 | Auryxia |
| Fresenius USA Marketing, INC. | $336.76 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $279.66 | 2021-2025 | |
| Amgen INC. | $235.77 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $231.92 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $197.30 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $176.13 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $174.04 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $159.64 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.38 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $126.95 | 2019-2024 | Injectafer |
| Novo Nordisk INC | $110.00 | 2021-2025 | Ozempic, Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.31 | 2019 | |
| Travere Therapeutics, INC. | $102.28 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $96.30 | 2025 | Rayaldee |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $88.94 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $88.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $68.16 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $65.56 | 2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $62.21 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $41.33 | 2020-2021 | |
| Ardelyx, INC. | $27.30 | 2024 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $24.91 | 2025 | |
| Genzyme Corporation | $22.72 | 2019 | |
| Shire North American Group INC | $17.94 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.67 | 2021 | |
| Boston Scientific Corporation | $17.19 | 2025 | General - Pain Management |
| Ani Pharmaceuticals, INC. | $16.44 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $15.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepu Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.